Applied BioCode Statistics
Total Valuation
Applied BioCode has a market cap or net worth of TWD 2.14 billion. The enterprise value is 1.67 billion.
Important Dates
The next estimated earnings date is Thursday, March 11, 2027.
| Earnings Date | Mar 11, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
Applied BioCode has 102.82 million shares outstanding.
| Current Share Class | 102.82M |
| Shares Outstanding | 102.82M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | 11.20% |
| Owned by Institutions (%) | 6.76% |
| Float | 71.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.94 |
| PB Ratio | 3.13 |
| P/TBV Ratio | 3.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.29 |
| EV / EBITDA | 214.38 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.07.
| Current Ratio | 6.12 |
| Quick Ratio | 4.64 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 5.91 |
| Debt / FCF | n/a |
| Interest Coverage | -13.00 |
Financial Efficiency
Return on equity (ROE) is -5.07% and return on invested capital (ROIC) is -4.09%.
| Return on Equity (ROE) | -5.07% |
| Return on Assets (ROA) | -3.33% |
| Return on Invested Capital (ROIC) | -4.09% |
| Return on Capital Employed (ROCE) | -5.36% |
| Weighted Average Cost of Capital (WACC) | 7.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, Applied BioCode has paid 238,000 in taxes.
| Income Tax | 238,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.22% in the last 52 weeks. The beta is 0.61, so Applied BioCode's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | +1.22% |
| 50-Day Moving Average | 27.32 |
| 200-Day Moving Average | 25.52 |
| Relative Strength Index (RSI) | 18.31 |
| Average Volume (20 Days) | 227,903 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Applied BioCode had revenue of TWD 728.39 million and -34.76 million in losses. Loss per share was -0.34.
| Revenue | 728.39M |
| Gross Profit | 446.18M |
| Operating Income | -48.43M |
| Pretax Income | -34.52M |
| Net Income | -34.76M |
| EBITDA | -14.42M |
| EBIT | -48.43M |
| Loss Per Share | -0.34 |
Full Income Statement Balance Sheet
The company has 514.83 million in cash and 46.04 million in debt, with a net cash position of 468.80 million or 4.56 per share.
| Cash & Cash Equivalents | 514.83M |
| Total Debt | 46.04M |
| Net Cash | 468.80M |
| Net Cash Per Share | 4.56 |
| Equity (Book Value) | 682.43M |
| Book Value Per Share | 6.64 |
| Working Capital | 777.01M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -101.02 million and capital expenditures -9.51 million, giving a free cash flow of -110.53 million.
| Operating Cash Flow | -101.02M |
| Capital Expenditures | -9.51M |
| Depreciation & Amortization | 34.01M |
| Net Borrowing | -18.99M |
| Free Cash Flow | -110.53M |
| FCF Per Share | -1.07 |
Full Cash Flow Statement Margins
Gross margin is 61.26%, with operating and profit margins of -6.65% and -4.77%.
| Gross Margin | 61.26% |
| Operating Margin | -6.65% |
| Pretax Margin | -4.74% |
| Profit Margin | -4.77% |
| EBITDA Margin | -1.98% |
| EBIT Margin | -6.65% |
| FCF Margin | n/a |
Dividends & Yields
Applied BioCode does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -1.63% |
| FCF Yield | -5.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Applied BioCode has an Altman Z-Score of 4.92 and a Piotroski F-Score of 2.
| Altman Z-Score | 4.92 |
| Piotroski F-Score | 2 |